Microfluidics as a high-throughput solution for chromatographic process development - The complexity of multimodal chromatography used as a proof of concept.

Antibody derivatives High-throughput process development Microfluidics Multimodal chromatography

Journal

Journal of chromatography. A
ISSN: 1873-3778
Titre abrégé: J Chromatogr A
Pays: Netherlands
ID NLM: 9318488

Informations de publication

Date de publication:
22 Nov 2021
Historique:
received: 29 04 2021
revised: 04 10 2021
accepted: 06 10 2021
pubmed: 20 10 2021
medline: 25 11 2021
entrez: 19 10 2021
Statut: ppublish

Résumé

High-throughput technologies are fundamental to expedite the implementation of novel purification platforms. The possibility of performing process development within short periods of time while saving consumables and biological material are prime features for any high-throughput screening device. In this work, a microfluidic device is evaluated as high-throughput solution for a complete study of chromatographic operation conditions on ten different multimodal resins. The potential of this class of purification solutions is generally hindered by its complexity. Taking this into consideration, the microfluidic platform was herein applied and assessed as a tool for high-throughput applications. The commercially available multimodal ligands were studied for the binding of three antibody-based biomolecules (polyclonal mixture of whole antibodies, Fab and Fc fragments) at different pH and salt conditions, in a total of 450 experiments. The results obtained with the microfluidic device were comparable to a standard 96-well filtering microplate high-throughput tool. Additionally, five of the ten multimodal ligands tested were packed into a bench-scale column to perform a final validation of the microfluidic results obtained. All the data acquired in this work using different screening protocols corroborate each other, showing that microfluidic chromatography is a valuable tool for the fast implementation of a new purification step, particularly, if the goal is to narrow the downstream possibilities by being a first point of decision.

Identifiants

pubmed: 34666268
pii: S0021-9673(21)00742-1
doi: 10.1016/j.chroma.2021.462618
pii:
doi:

Substances chimiques

Ligands 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

462618

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

André Nascimento (A)

iBB - Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal.

Mariana N São Pedro (MN)

iBB - Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal.

Inês F Pinto (IF)

iBB - Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal; Instituto de Engenharia de Sistemas e Computadores - Microsistemas e Nanotecnologias (INESC MN) and IN - Institute of Nanoscience and Nanotechnology, Lisbon, Portugal.

Maria Raquel Aires-Barros (MR)

iBB - Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal; Department of Bioengineering, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal.

Ana M Azevedo (AM)

iBB - Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal; Department of Bioengineering, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal. Electronic address: a.azevedo@tecnico.ulisboa.pt.

Articles similaires

Humans Chondrocytes Osteoarthritis Matrix Metalloproteinase 13 Drug Discovery
Receptor, Cannabinoid, CB1 Ligands Molecular Dynamics Simulation Protein Binding Thermodynamics
Proteins Protein Binding Ligands Internet Databases, Protein

Orientation-dependent CD45 inhibition with viral and engineered ligands.

Marta T Borowska, Liu D Liu, Nathanael A Caveney et al.
1.00
Leukocyte Common Antigens Humans Ligands T-Lymphocytes Viral Proteins

Classifications MeSH